Boston Scientific Corporation BSX said it received FDA approval for the EMBLEM MRI Subcutaneous Implantable Defibrillator (S-ICD) System and magnetic resonance (MR) conditional labeling for all its earlier implanted EMBLEM S-ICD Systems. The approval enabled the company to add the device to its growing line of ImageReady MR-conditional devices.
The company indicated the devices enable patients to undergo magnetic resonance imaging (MRI) safely. It claimed the system is a proved treatment option for patients, who are at a risk of sudden cardiac arrest.
Boston Scientific's chief medical officer for Rhythm Management, Kenneth Stein, said, "Now with FDA approval, patients receiving the EMBLEM MRI S-ICD System, as well as patients who previously were implanted with an EMBLEM S-ICD System, have reassurance they can safely undergo MR scans while remaining protected from cardiac arrest."
The company got FDA approval for its ImageReady MR-Conditional Pacing System earlier in the current year. That included ESSENTIO and ACCOLADE MRI pacemakers and INGEVITY MRI pacing leads meant to treat bradycardia.
On Monday, the stock shed $0.26, or 1.06 percent, to $23.88.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.